Table 1.

Patient characteristics.

CharacteristicNumber (%)CDKL3 (−)CDKL3 (+)P-value
Gender0.446
 Female61 (40.1)32 (43.2)29 (37.2)
 Male91 (59.9)42 (56.8)49 (62.8)
Age/year0.888
 <1871 (46.7)35 (47.3)36 (46.2)
 ≥1881 (53.3)39 (52.7)42 (53.8)
Tumor site1a
 Extremities148 (97.4)72 (97.3)76 (97.4)
 Non-extremities4 (2.6)2 (2.7)2 (2.6)
Enneking’s surgical staging0.396
 I/II141 (92.8)70 (94.6)71 (91.0)
 III11 (7.2)4 (5.4)7 (9.0)
Karnofsky performance status score0.726a
 ≥80146 (96.1)72 (97.3)74 (94.9)
 ≤706 (3.9)2 (2.7)4 (5.1)
Neoadjuvant chemotherapy1b
 Yes150 (98.7)73 (98.6)77 (91.0)
 No2 (1.3)1 (1.4)1 (9.0)
Pathological subtype0.242
 Conventional136 (89.5)64 (86.5)72 (92.3)
 Telangiectatic16 (10.5)10 (13.5)6 (7.7)
Surgical0.173
 Amputation47 (30.9)19 (25.7)28 (35.9)
 Limb salvage105 (69.1)55 (74.3)50 (64.1)
Local recurrence0.851
 Yes38 (25.0)18 (24.3)20 (25.6)
 No114 (75.0)56 (75.7)58 (74.4)
Metastasis0.024
 Yes94 (61.8)39 (52.7)55 (70.5)
 No58 (38.2)35 (47.3)23 (29.5)
  • Pearson’s chi-squared test was used to compare clinical differences between patients with negative or positive of CDKL3.

  • a Continuous correction chi-square test.

  • b Fisher’s exact test.